Comments on: RNA-drug developer Quark aims for $30M after failed IPO http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/ News About Tech, Money and Innovation Wed, 25 Nov 2009 02:43:52 +0000 http://wordpress.org/?v=2.8.5 hourly 1 By: Life-science briefing: Monday, April 7, 2008 » VentureBeat http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/comment-page-1/#comment-802431 Life-science briefing: Monday, April 7, 2008 » VentureBeat Tue, 08 Apr 2008 13:39:57 +0000 http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/#comment-802431 [...] drugs, raised $27 million in an eighth funding round. The company’s fundraising follows a failed attempt to go public last year, and reflects a somewhat smaller haul than the $30 million it had hoped to [...] [...] drugs, raised $27 million in an eighth funding round. The company’s fundraising follows a failed attempt to go public last year, and reflects a somewhat smaller haul than the $30 million it had hoped to [...]

]]> By: Quark Pharma update: Not quite such a chameleon, after all » VentureBeat http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/comment-page-1/#comment-795646 Quark Pharma update: Not quite such a chameleon, after all » VentureBeat Mon, 18 Feb 2008 23:42:10 +0000 http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/#comment-795646 [...] what are now Quark’s leading RNAi drug candidates. These are the statements I alluded to in an earlier post, in which I quoted Quark CEO Danny Zurr saying that Silence had been “deceiving the [...] [...] what are now Quark’s leading RNAi drug candidates. These are the statements I alluded to in an earlier post, in which I quoted Quark CEO Danny Zurr saying that Silence had been “deceiving the [...]

]]> By: Eric http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/comment-page-1/#comment-763576 Eric Thu, 31 Jan 2008 13:15:54 +0000 http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/#comment-763576 Technically, the licenses with Silence (and also Alnylam) are really to gain FTO to use siRNAs therapeutically for several gene targets of interest. Quark probably knew they wanted to target these proteins (p53 and RTP801) through their discovery platform and/or collaborations they had in place. Zucker probably objected to the term new-comer to differentiate themselves from the "really" new players, e.g. Dicerna Technically, the licenses with Silence (and also Alnylam) are really to gain FTO to use siRNAs therapeutically for several gene targets of interest. Quark probably knew they wanted to target these proteins (p53 and RTP801) through their discovery platform and/or collaborations they had in place.

Zucker probably objected to the term new-comer to differentiate themselves from the “really” new players, e.g. Dicerna

]]> By: VentureBeat » RNA-drug developer Quark aims for $30M after failed IPO http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/comment-page-1/#comment-757766 VentureBeat » RNA-drug developer Quark aims for $30M after failed IPO Mon, 28 Jan 2008 23:00:15 +0000 http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/#comment-757766 [...] our story on this Fremont, Calif., developer of RNA-interference drugs at VentureBeat Life Sciences. Tagged [...] [...] our story on this Fremont, Calif., developer of RNA-interference drugs at VentureBeat Life Sciences. Tagged [...]

]]> By: VentureBeat » RNA-drug developer Quark aims for $30M after failed IPO http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/comment-page-1/#comment-757752 VentureBeat » RNA-drug developer Quark aims for $30M after failed IPO Mon, 28 Jan 2008 23:00:15 +0000 http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/#comment-757752 [...] our story on this Fremont, Calif., developer of RNA-interference drugs at VentureBeat Life Sciences. Tagged [...] [...] our story on this Fremont, Calif., developer of RNA-interference drugs at VentureBeat Life Sciences. Tagged [...]

]]>